Narayana Hrudayalaya's India hospital EBITDA growth supports valuation despite insurance losses

Investment View and Recommendation

Kotak Securities Private Client Group, in its company update dated August 24, 2026, has upgraded Narayana Hrudayalaya to BUY with a 12-month fair value of Rs2,350. The constructive view is based primarily on continued delivery by the core India hospital business, which reported 39 per cent year-on-year EBITDA growth in Q1FY27, despite losses in the insurance verticals weighing on sentiment.

Insurance Businesses and Path to Recovery

Narayana Hrudayalaya's stock had been under pressure following Q1FY27 losses of about Rs20 crore in the Indian insurance business and about Rs35 crore in the Cayman insurance business. The major concern is the elevated 219 per cent claims ratio in the Indian insurance vertical, which Kotak attributes mainly to higher exposure to group policies written in the previous year.

Kotak estimates that the Indian insurance and clinics businesses will report an operating loss of Rs120 crore in FY27E. The broker expects Narayana Hrudayalaya to slow its issuance of group policies and increase the retail-policy mix. This should gradually bring down the Indian insurance claims ratio from the Q1FY27 level.

The Cayman insurance venture is viewed more favourably because of Narayana Hrudayalaya's dominant healthcare presence there and strong customer renewal behaviour after repricing. One-third of Cayman contracts were repriced in July 2026, with a 100 per cent renewal rate. Kotak is confident that a similar outcome can be achieved during the January 2027 repricing cycle and expects the Cayman insurance operation to break even by the end of FY28E.

Core India Hospital Growth Outlook

The core India hospital segment remains the central earnings driver. Kotak highlights an 18 per cent EBITDA CAGR over FY23-FY26 and forecasts a 14 per cent EBITDA CAGR over FY26-FY29E.

The broker considers execution risk from capacity expansion relatively contained because most upcoming bed additions are in Narayana Hrudayalaya's core markets and are more back-ended.

Valuation

At the report CMP of Rs1,816, Kotak values the India hospital business at about 17 times FY28E pre-Ind AS 116 EV/EBITDA. The broker considers this valuation attractive given the core hospital business's growth profile, supporting the BUY rating and the Rs2,350 fair value.

Key Risks to the Investment Thesis

• Persistently high claims in the Indian insurance business.
• Continuing operating losses in Indian insurance and clinics.
• Failure of Cayman repricing and renewal trends to support the path to break-even.